Breaking News

Today Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
SAGE Sage Therapeutics $121.50 -9.46 (-7.22%) 07:38 11/13/18 11/13 07:38 11/13/18 07:38 Initiation	Sage Therapeutics initiated at Leerink » Sage Therapeutics… Sage Therapeutics initiated with an Underperform at Leerink. Leerink analyst Marc Goodman started Sage Therapeutics with an Underperform and $80 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Sage Therapeutics, while Goodman sees lead asset Zulresso being approved by year end and enabling Sage to establish a commercial organization in the U.S. and EU, he expects a very slow ramp and believes this will be a niche product. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	14 Nov 27 Nov 19 Dec

Yesterday
HUYA Huya $18.50 -0.5 (-2.63%) , MFIN Medallion Financial $6.80 -0.23 (-3.27%) … 18:31 11/12/18 11/12 18:31 11/12/18 18:31 Hot Stocks	Fly Intel: After Hours Movers » UP AFTER EARNINGS: Huya… UP AFTER EARNINGS: Huya Inc (HUYA) up 8.1%... Medallian Financial (MFIN) up 3.7%. DOWN AFTER EARNINGS: Eventbrite (EB) down 6.8%... Yirendai (YRD) down 4.7%... Kornit Digital (KRNT) down 0.8%. ALSO LOWER: Maiden Holdings (MHLD) down 4.2% after reports that Catalina will not bid for company... Sage Therapeutics (SAGE) down 2.3% after being initiated at Underperform at Leerink. HUYA Huya $18.50 -0.5 (-2.63%) MFIN Medallion Financial $6.80 -0.23 (-3.27%) EB Eventbrite $30.90 -1.6 (-4.92%) YRD Yirendai $15.47 -1.75 (-10.16%) KRNT Kornit Digital $19.15 -0.88 (-4.39%) MHLD Maiden Holdings $2.40 -1.12 (-31.82%) SAGE Sage Therapeutics $121.50 -9.46 (-7.22%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Nov 12 Nov 12 Nov 12 Nov 13 Nov 14 Nov 27 Nov 19 Dec
SAGE Sage Therapeutics $121.50 -9.46 (-7.22%) 16:45 11/12/18 11/12 16:45 11/12/18 16:45 Initiation	Sage Therapeutics initiated at Leerink » Sage Therapeutics… Sage Therapeutics initiated with an Underperform at Leerink. Leerink Partners analyst Marc Goodman started Sage Therapeutics with an Underperform rating and $80 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	14 Nov 27 Nov 19 Dec

Friday
SAGE Sage Therapeutics $132.84 (0.00%) 09:45 11/09/18 11/09 09:45 11/09/18 09:45 Conference/Events	Sage Therapeutics has a conference call hosted by JPMorgan » JPMorgan Analyst Kasimov… JPMorgan Analyst Kasimov will host a conference call with CEO Jeff Jonas on November 9 at 10 am. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Nov 14 Nov 27 Nov 19 Dec
SAGE Sage Therapeutics $132.84 2.46 (1.89%) 04:55 11/09/18 11/09 04:55 11/09/18 04:55 Conference/Events	Sage Therapeutics has a conference call hosted by JPMorgan » JPMorgan Analyst Kasimov… JPMorgan Analyst Kasimov will host a conference call with CEO Jeff Jonas on November 9 at 10 am. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Nov 14 Nov 27 Nov 19 Dec

Thursday
SAGE Sage Therapeutics $132.84 2.46 (1.89%) 20:04 11/08/18 11/08 20:04 11/08/18 20:04 Conference/Events	Sage Therapeutics has a conference call hosted by JPMorgan » JPMorgan Analyst Kasimov… JPMorgan Analyst Kasimov will host a conference call with CEO Jeff Jonas on November 9 at 10 am. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Nov 14 Nov 27 Nov 19 Dec

Over a week ago
SAGE Sage Therapeutics $128.36 1.74 (1.37%) 20:23 11/06/18 11/06 20:23 11/06/18 20:23 Recommendations	Sage Therapeutics analyst commentary at BMO Capital » BMO Capital optimistic… BMO Capital optimistic about Sage Therapeutics upcoming data readouts. BMO Capital analyst Gary Nachman kept his Outperform rating and $203 price target on Sage Therapeutics after its Q3 results, saying the company's "much higher SG&A" spending is "supporting preparations for an expected launch of Zulresso" for postpartum depression in March of 2019. The analyst anticipates approval for Zulresso by the December PDUFA following a "very favorable AdComm last week". Nachman is also positive on Sage Therapeutics' development of trials for SAGE-217 in major depressive disorders, which he claims may be "an even bigger opportunity if successful". 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	06 Nov 06 Nov 27 Nov 19 Dec
SAGE Sage Therapeutics $126.24 -0.38 (-0.30%) 14:18 11/06/18 11/06 14:18 11/06/18 14:18 Recommendations	Sage Therapeutics analyst commentary » Sage Therapeutics pricing… Sage Therapeutics pricing for Zulresso at a premium to Piper Jaffray estimate. Piper Jaffray analyst Danielle Brill, who maintained an Overweight rating and $206 price target on Sage Therapeutics shares, noted that the announced plans to price Zulresso at $25,000-$35,000 per course -- should it be approved on its December 19 PDUFA date -- which is at a premium to Piper's estimated net pricing of $15,000. Brill also noted that the drug's sales force has been hired, which includes ~130 reps, and ~50 patient support/access personnel, and she is awaiting final commercial details following PDUFA announcement. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	06 Nov 06 Nov 27 Nov 19 Dec
BLUE Bluebird Bio $136.36 3.93 (2.97%) , SAGE Sage Therapeutics $126.62 -10.64 (-7.75%) … 08:20 11/06/18 11/06 08:20 11/06/18 08:20 Conference/Events	RBC Capital to hold a bus tour » Biotech Bus Tour travels… Biotech Bus Tour travels throughout Boston on November 6. BLUE Bluebird Bio $136.36 3.93 (2.97%) SAGE Sage Therapeutics $126.62 -10.64 (-7.75%) SRPT Sarepta $139.53 -6.32 (-4.33%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	06 Nov 06 Nov 12 Nov 27 Nov 01 Dec 03 Dec 13 Dec 19 Dec
SAGE Sage Therapeutics $126.62 -10.64 (-7.75%) 07:55 11/06/18 11/06 07:55 11/06/18 07:55 Conference/Events	Sage Therapeutics to hold a conference call on FDA meeting » Management discusses the… Management discusses the FDA's joint advisory committees favorable decision in support of the Company's New Drug Application for ZULPRESSO (Brexanolone) for treatment of Postpartum Depression, as well as 3Q earnings results, on a conference call to be held on November 6 at 8 am. Webcast Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	06 Nov 06 Nov 27 Nov 19 Dec

On The Fly

News and insights, exclusive to thefly.com

20:25	Notable companies reporting before tomorrow's open»
19:01	Fly Intel: After Hours Movers»
12:47	Notable companies reporting before tomorrow's open»
12:47	Notable companies reporting after market close»
10:44	Fly Intel: What to watch in Macy's earnings report»

View all On The Fly Stories »

Upcoming
Events (10)

VAPO	Vapotherm - VAPO
TBPH ...	PDUFA Date for Revefenacin
CPE ...	Whispering Pines Energy Round Table
SMG ...	Global Consumer & Retail Conference
RPD ...	Networking, Communications & Security Conference
	UBS European Conference
MLNX ...	Silicon Valley Field Trip
FIVN ...	Technology, Internet, Media & Telecom Conference
	Restaurant Finance & Development Conference
LRCX ...	Global Technology Conference

View all of today’s events »

Today’s
Syndicate (0)

No syndicate deals for your search.

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial